



Manhattan Scientifics Former Wholly Owned Sub Announces Breast Cancer Diagnostic Test Begins with First-in-Human Study

Has Breast Cancer Spread To The Lymph Nodes?

NEW YORK—Dec. 16, 2020—Manhattan Scientifics Inc. (MHTX: OTCQB) announces that the first 15-person human study to provide a safety assessment for the company's use of Nanoparticles for breast cancer detection is underway at Imagion Biosystems Inc. Trades as [IBX.AX](#).

The study is the first clinical investigation of Imagion Biosystems' MagSense™ nanoparticles that target HER2 positive tumor cells as a means of helping in breast cancer diagnosis by identifying if patient's tumor has spread to the lymph nodes.

Manhattan Scientifics Inc, an American medical technology incubator that seed funded IBX and then spun it out as a public company on the Australian stock exchange. Manhattan Scientifics owns more than 50 million IBX shares and remains as the largest single shareholder of IBX.

To learn more about the study visit the link below;

[Imagion Biosystems first in-human study update - webcast presentation](#)

About Manhattan Scientifics, Inc.

Manhattan Scientifics Inc. (www.mhtx.com) is focused on technology transfer and commercialization of transformative technologies.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Contacts

Manhattan Scientifics, Inc.
Manny Tsoupanarias, 917-688-4158
Manny@mhtx.com

Or

Marvin Maslow, 917-923-3300
Marvin@mhtx.com